Mechanistic signatures of HPV insertions in cervical Carcinomas

npj Genomic Medicine

Volumn 1, Issue , 2016, Pages

  Holmes, Allyson ^a   Lameiras, Sonia ^a   Jeannot, Emmanuelle ^a   Marie, Yannick ^b   Castera, Laurent ^c   Sastre Garau, Xavier ^a,d   Nicolas, Alain ^a  

^a INSTITUT CURIE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CENTRE FRANÇOIS BACLESSE   (France)

^d Institut de Cancérologie de Lorraine Alexis Vautrin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84995814141     PISSN: None     EISSN: 20567944     Source Type: Journal    
DOI: 10.1038/npjgenmed.2016.4     Document Type: Article

References (41)

1. Forman, D. et al. Global burden of human papillomavirus and related diseases. Vaccine 30 Suppl 5, F12-F23 (2012).
2. Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C. & Wacholder, S. Human papillomavirus and cervical cancer. Lancet 370, 890-907 (2007).
3. Alemany, L. et al. Time trends of human papillomavirus types in invasive cervical cancer, from 1940 to 2007. Int. J. Cancer 135, 88-95 (2014).
4. Fotopoulou, C. et al. Long-Term clinical outcome of pelvic exenteration in patients with advanced gynecological malignancies. J. Surg. Oncol. 101, 507-512 (2010).
5. Khoury-Collado, F. et al. Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol. Oncol. 124, 42-47 (2012).
6. Peiretti, M. et al. Management of recurrent cervical cancer: A review of the literature. Surg. Oncol. 21, e59-e66 (2012).
7. Lorincz, A. T. et al. Human papillomavirus infection of the cervix: Relative risk associations of 15 common anogenital types. Obstetrics & Gyn. 79, 328-337 (1992).
8. Walboomers, J. M. et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999).
9. Castellsagué, X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol. Oncol. 110, S4-S7 (2008).
10. De Cremoux, P. et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. Int. J. Cancer 124, 778-782 (2009).
11. De Sanjose, S. et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11, 1048-1056 (2010).
12. Moody, C. A. & Laimins, L. A. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10, 550-560 (2010).
13. Schneider-Maunoury, S., Croissant, O. & Orth, G. Integration of human papillomavirus type 16 DNA sequences: A possible early event in the progression of genital tumors. J. Virol. 61, 3295-3298 (1987).
14. Couturier, J., Sastre-Garau, X., Schneider-Maunoury, S., Labib, A. & Orth, G. Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression. J. Virol. 65, 4534-4538 (1991).
15. Wentzensen, N., Vinokurova, S. & von Knebel Doeberitz, M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 64, 3878-3884 (2004).
16. Peters, W. A. et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 18, 1606-1613 (2000).
17. Xu B. et al. Multiplex Identification of Human Papillomavirus 16 DNA Integration Sites in Cervical Carcinomas. PLoS ONE 2013; 8: E66693.
18. Marongiu, L., Godi, A., Parry, J. V. & Beddows, S. Human Papillomavirus 16, 18, 31 and 45 viral load, integration and methylation status stratified by cervical disease stage. BMC Cancer 14, 384 (2014).
19. Shin, H.-J., Joo, J., Yoon, J. H., Yoo, C. W. & Kim, J.-Y. Physical status of human papillomavirus integration in cervical cancer is associated with treatment outcome of the patients treated with radiotherapy. PLoS ONE 9, e78995 (2014).
20. Hu, Z. et al. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat. Genet. 47, 158-163 (2015).
21. Herrick, J. et al. Genomic organization of amplified MYC genes suggests distinct mechanisms of amplification in tumorigenesis. Cancer Res. 65, 1174-1179 (2005).
22. Peter, M. et al. MYC activation associated with the integration of HPV DNA at the MYC locus in genital tumors. Oncogene 25, 5985-5993 (2006).
23. Peter, M. et al. Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J. Pathol. 221, 320-330 (2010).
24. Bodily, J. & Laimins, L. A. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 19, 33-39 (2011).
25. Campitelli, M. et al. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients. PLoS ONE 7, e43393 (2012).
26. Luft, F. et al. Detection of integrated papillomavirus sequences by ligation-mediated PCR (DIPS-PCR) and molecular characterization in cervical cancer cells. Int. J. Cancer 92, 9-17 (2001).
27. Akagi, K. et al. Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability. Genome Res. 24, 185-199 (2014).
28. Li, N., Franceschi, S., Howell-Jones, R., Snidjers, P. J. & Clifford, G. M. Human papillomavirus type distribution in 30, 848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int. J. Cancer 128, 927-935 (2011).
29. Hong, H., He, T. F., Ni, H. X., Zhang, S. & Xu, G. Z. Prevalence and genotype distribution of HPV infection among women in Ningbo. China Int. J. Gyn. Obstet. 96-99 (2015).
30. Ojesina, A. et al. Landscape of genomic alterations in cervical carcinomas. Nature 506, 371-375 (2014).
31. Orr-Weaver, T. L., Szostak, J. W. & Rothstein, R. J. Yeast transformation: A model system for the study of recombination. Proc. Natl Acad. Sci. USA 78, 6354-6358 (1981).
32. Jasin, M. & Rothstein, R. Repair of strand breaks by homologous recombination. Cold Spring Harb. Perspect. Biol. 5, a012740 (2013).
33. Hastings, P. J., Ira, G. & Lupski, J. R. A microhomology-mediated break-induced replication model for the origin of human copy number variation. PLoS Genet. 5, e1000327 (2009).
34. Fenton, J. et al. [Invasive cancer of the uterine cervix in young women: Retrospective study of 236 cases]. Bull. Cancer 77, 109-116 (1990).
35. Olsson, E. et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol. Med. 1-15 (2015).
36. Rusan, M., Li, Y. Y. & Hammerman, P. S. Genomic landscape of human papillomavirus-Associated cancers. Clin. Cancer Res. 1-12 (2015).
37. Muller, E. et al. Genetic profiles of cervical tumors by high-Throughput sequencing for personalized medical care. Cancer Med. (2015).
38. Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838-1847 (2009).
39. Pang, C. L. & Thierry, F. Human papillomavirus proteins as prospective therapeutic targets. Microb. Pathog. 58, 55-65 (2013).
40. Chaturvedi, A. K. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29, 4294-4301 (2011).
41. Popova, T. et al. Genome Alteration Print (GAP): A tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol. 10, R128 (2009).